Denali Therapeutics (DNLI) Total Current Liabilities (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Total Current Liabilities data on file, last reported at $110.2 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $110.2 million, up 19.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $110.2 million (up 19.9% YoY), and the FY2025 annual result was $98.4 million, down 3.77% from the prior year.
• Total Current Liabilities grew to $110.2 million in Q1 2026 per DNLI's latest filing, from $98.4 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $391.1 million in Q1 2023 and troughed at $69.4 million in Q2 2023.
• A 5-year average of $167.7 million and a median of $91.9 million in 2025 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities surged 577.2% in 2022, then slumped 80.26% in 2023.
• A 5-year view of Total Current Liabilities shows it stood at $363.9 million in 2022, then slumped by 78.57% to $78.0 million in 2023, then soared by 31.07% to $102.2 million in 2024, then slipped by 3.77% to $98.4 million in 2025, then rose by 12.0% to $110.2 million in 2026.
• Business Quant data shows DNLI's Total Current Liabilities at $110.2 million in Q1 2026, $98.4 million in Q4 2025, and $90.1 million in Q3 2025.